Adaptimmune Therapeutics plc Overview
Pro stress-test →Adaptimmune Therapeutics plc is a commercial-stage biopharmaceutical company providing novel cell therapies primarily to cancer patients in the United States and the United Kingdom. The company develops TECELRA (famitresgene autoleucel), a genetically modified autologous T-cell immunotherapy for unresectable or metastatic synovial sarcoma, along with Lete-cel and ADP-5701 candidates in development.
Strategic Profile
Pro stress-test →Adaptimmune is working to redefine the treatment of solid tumor cancers with cell therapies, using a proprietary platform to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates. The company has achieved commercial traction with TECELRA and strategic partnerships including a collaboration with Galápagos and alliance with MD Anderson Cancer Center.
Competitive Landscape
Pro stress-test →Adaptimmune competes in the cell therapy and cancer immunotherapy space against companies developing TCR therapies and CAR-T approaches. Competitors include NexImmune and approximately 54 other similar-stage companies. The company has partnered with Galápagos and MD Anderson to strengthen competitive positioning.
Industry Context
Adaptimmune Therapeutics plc operates in Biopharmaceutical / Cell Therapy / Cancer Immunotherapy.
Key facts
Founded: 2008 · Headquarters: Abingdon, United Kingdom · Employees: 506 · Revenue: $178.03M (2024) · Market cap: $7.69M